{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:49:12Z","timestamp":1790689752898,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bmc.2022.117129","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T11:23:18Z","timestamp":1670844198000},"page":"117129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Harnessing polyhydroxylated pyrrolidines as a stabilizer of acid alpha-glucosidase (GAA) to enhance the efficacy of enzyme replacement therapy in Pompe disease"],"prefix":"10.1016","volume":"78","author":[{"given":"Huang-Yi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni-Chung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Chung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Li","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chieh","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2022.117129_b0005","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.bmc.2022.117129_b0010","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2022.117129_b0015","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2174\/138920111795542606","article-title":"Pompe disease: from new views on pathophysiology to innovative therapeutic strategies","volume":"12","author":"Parenti","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.bmc.2022.117129_b0020","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00415-021-10526-5","article-title":"Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis","volume":"269","author":"Sarah","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.bmc.2022.117129_b0025","doi-asserted-by":"crossref","first-page":"e98336","DOI":"10.1371\/journal.pone.0098336","article-title":"Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent","volume":"9","author":"Nayak","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2022.117129_b0030","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.bmc.2022.117129_b0035","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.bmc.2022.117129_b0040","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3389\/fphar.2019.01450","article-title":"From Synthesis to Characterization of Site-Selective PEGylated Proteins","volume":"10","author":"Bel\u00e9n","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2022.117129_b0045","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1039\/C9TB00590K","article-title":"PEGylation as an efficient tool to enhance cytochrome c thermostability: a kinetic and thermodynamic study","volume":"7","author":"Santos","year":"2019","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.bmc.2022.117129_b0050","doi-asserted-by":"crossref","first-page":"14313","DOI":"10.1021\/ja036833h","article-title":"Iminosugar Glycosidase Inhibitors: Structural and Thermodynamic Dissection of the Binding of Isofagomine and 1-Deoxynojirimycin to \u03b2-Glucosidases","volume":"125","author":"Zechel","year":"2003","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2022.117129_b0055","doi-asserted-by":"crossref","first-page":"7383","DOI":"10.1039\/C7SC01540B","article-title":"Determination of protonation states of iminosugar\u2013enzyme complexes using photoinduced electron transfer","volume":"8","author":"Wang","year":"2017","journal-title":"Chem Sci"},{"key":"10.1016\/j.bmc.2022.117129_b0060","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1021\/jm300171v","article-title":"Design, Synthesis, and Biological Evaluation of N-Alkylated Deoxynojirimycin (DNJ) Derivatives for the Treatment of Dengue Virus Infection","volume":"55","author":"Yu","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.117129_b0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1124\/mol.61.1.186","article-title":"The \u03b1-Glucosidase Inhibitor 1-Deoxynojirimycin Blocks Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Membrane Fusion at the CXCR4 Binding Step","volume":"61","author":"Papandr\u00e9ou","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmc.2022.117129_b0070","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.bmc.2022.117129_b0075","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S a-glucosidase: A therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2022.117129_b0080","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/humu.21121","article-title":"The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase","volume":"30","author":"Flanagan","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.bmc.2022.117129_b0085","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1016\/j.bmc.2013.06.054","article-title":"Rapid modifications of N-substitution in iminosugars: Development of new \u03b2-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease","volume":"21","author":"Cheng","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2022.117129_b0090","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/mt.2014.138","article-title":"A Chaperone Enhances Blood \u03b1-Glucosidase Activity in Pompe Disease Patients Treated With Enzyme Replacement Therapy","volume":"22","author":"Parenti","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.bmc.2022.117129_b0095","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ymthe.2017.02.017","article-title":"Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid \u03b1-Glucosidase in Pompe Patients Co-administered with Alglucosidase \u03b1","volume":"25","author":"Kishnani","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.bmc.2022.117129_b0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2016.07.025","article-title":"Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency","volume":"123","author":"Cheng","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.117129_b0105","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1172\/JCI34355","article-title":"Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria","volume":"118","author":"Pey","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmc.2022.117129_b0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/1875397301004010067","article-title":"High throughput screening for inhibitors of alpha-galactosidase","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr. Chem. Genomics"},{"key":"10.1016\/j.bmc.2022.117129_b0115","first-page":"1214","article-title":"A thermodynamic assay to test pharmacological chaperones for Fabry disease","volume":"1840","author":"Andreotti","year":"2014","journal-title":"BBA"},{"key":"10.1016\/j.bmc.2022.117129_b0120","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/ajoc.201900637","article-title":"Divergent Synthesis of Bicyclic Iminosugars: Preparation of (\u2212)-Swainsonine-Based Alkaloids and Their Inhibition Study towards \u03b1-Human Mannosidases","volume":"8","author":"Chen","year":"2019","journal-title":"Asian J Org Chem"},{"key":"10.1016\/j.bmc.2022.117129_b0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ijch.201400140","article-title":"Synthesis and Inhibition Study of Bicyclic Iminosugar-Based Alkaloids, Scaffolds, and Libraries towards Glucosidase","volume":"55","author":"Cheng","year":"2015","journal-title":"Isr J Chem"},{"key":"10.1016\/j.bmc.2022.117129_b0130","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1039\/C7CC09642A","article-title":"A combinatorial approach towards the synthesis of non-hydrolysable triazole\u2013iduronic acid hybrid inhibitors of human \u03b1-l-iduronidase: discovery of enzyme stabilizers for the potential treatment of MPSI","volume":"54","author":"Cheng","year":"2018","journal-title":"Chem Commun"},{"key":"10.1016\/j.bmc.2022.117129_b0135","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ejmech.2017.12.036","article-title":"Synthesis of (3S,4S,5S)-trihydroxylpiperidine derivatives as enzyme stabilizers to improve therapeutic enzyme activity in Fabry patient cell lines","volume":"144","author":"Li","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.117129_b0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tet.2008.10.096","article-title":"A convenient approach toward the synthesis of enantiopure isomers of DMDP and ADMDP","volume":"65","author":"Tsou","year":"2009","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmc.2022.117129_b0145","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1002\/asia.201300680","article-title":"From Natural Product-Inspired Pyrrolidine Scaffolds to the Development of New Human Golgi \u03b1-Mannosidase II Inhibitors","volume":"8","author":"Cheng","year":"2013","journal-title":"Chem Asian J"},{"key":"10.1016\/j.bmc.2022.117129_b0150","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/dta.1798","article-title":"Looking for protein stabilizing drugs with thermal shift assay","volume":"7","author":"Andreotti","year":"2015","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bmc.2022.117129_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2016.10.004","article-title":"Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease","volume":"126","author":"Cheng","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.117129_b0160","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/S0040-4039(00)98635-0","article-title":"Identification of the 2-hydroxymethyl-3,4-dihydroxypyrrolidine (or 1,4-dideoxy-1,4-iminopentitol) from angylocalyx boutiqueanus and from arachniodes standishii as the (2R, 3R, 4S)-isomer by the synthesis of its enantiomer","volume":"26","author":"Jones","year":"1985","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2022.117129_b0165","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0031-9422(00)94435-2","article-title":"2,5-Dihydroxymethyl 3,4-dihydroxypyrrolidine dans les feuilles de Derris elliptica","volume":"15","author":"Welter","year":"1976","journal-title":"Phytochemistry"},{"key":"10.1016\/j.bmc.2022.117129_b0170","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1021\/jo00206a037","article-title":"Synthesis of 2(R),5(R)-bis(hydroxymethyl)-3(R),4(R)-dihydroxypyrrolidine. A novel glycosidase inhibitor","volume":"50","author":"Card","year":"1985","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2022.117129_b0175","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s41467-017-01263-3","article-title":"Structure of human lysosomal acid \u03b1-glucosidase\u2013a guide for the treatment of Pompe disease","volume":"8","author":"Roig-Zamboni","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2022.117129_b0180","unstructured":"C.W.-C.L.H.-Y.H.W.-L.C.Y.-H.L. Ni-Chung, Methods of treating Pompe disease, provisional patent US62\/910,552, October 4, 2019."},{"key":"10.1016\/j.bmc.2022.117129_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25122843","article-title":"Strategy for Designing Selective Lysosomal Acid \u03b1-Glucosidase Inhibitors: Binding Orientation and Influence on Selectivity","volume":"25","author":"Kato","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2022.117129_b0190","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/S0040-4039(00)98636-2","article-title":"Potent competitive inhibition of \u03b1-galactosidase and \u03b1-glucosidase activity by 1,4-dideoxy-1,4-iminopentitols: syntheses of 1,4-dideoxy-1,4-imino-d-lyxitol and of both enantiomers of 1,4-dideoxy-1,4-iminoarabinitol","volume":"26","author":"Fleet","year":"1985","journal-title":"Tetrahedron Lett"},{"issue":"23","key":"10.1016\/j.bmc.2022.117129_b0195","doi-asserted-by":"crossref","first-page":"9462","DOI":"10.1021\/acs.jmedchem.7b00646","article-title":"N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of \u03b1-Glucosidase Activity for the Treatment of Pompe Disease","volume":"60","author":"D\u2019Alonzo","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.117129_b0200","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1021\/ol201552q","article-title":"Looking-Glass Synergistic Pharmacological Chaperones: DGJ and L-DGJ from the Enantiomers of Tagatose","volume":"13","author":"Jenkinson","year":"2011","journal-title":"Org Lett"},{"key":"10.1016\/j.bmc.2022.117129_b0205","doi-asserted-by":"crossref","first-page":"10347","DOI":"10.1021\/jm301304e","article-title":"\u03b1-1-C-Butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a Second-Generation Iminosugar-Based Oral \u03b1-Glucosidase Inhibitor for Improving Postprandial Hyperglycemia","volume":"55","author":"Kato","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.117129_b0210","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","article-title":"The Molecular Basis of Pharmacological Chaperoning in Human \u03b1-Galactosidase","volume":"18","author":"Guce","year":"2011","journal-title":"Chem Biol"},{"key":"10.1016\/j.bmc.2022.117129_b0215","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1093\/emboj\/20.12.3008","article-title":"Structure of Golgi alpha-mannosidase II: a target for inhibition of growth and metastasis of cancer cells","volume":"20","author":"van den Elsen","year":"2001","journal-title":"EMBO J"},{"issue":"9","key":"10.1016\/j.bmc.2022.117129_b0220","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2018030329","article-title":"Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J Am Soc Nephrol"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622005223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622005223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:19:43Z","timestamp":1760836783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089622005223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":44,"alternative-id":["S0968089622005223"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2022.117129","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing polyhydroxylated pyrrolidines as a stabilizer of acid alpha-glucosidase (GAA) to enhance the efficacy of enzyme replacement therapy in Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2022.117129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117129"}}